Please login to the form below

Not currently logged in
Email:
Password:

Tasigna

This page shows the latest Tasigna news and features for those working in and with pharma, biotech and healthcare.

Novartis eyes 2021 regulatory submissions for ‘STAMP’ inhibitor asciminib

Novartis eyes 2021 regulatory submissions for ‘STAMP’ inhibitor asciminib

If asciminib is approved it will add to Novartis’ existing portfolio of blood cancer treatments, including Gilvec and Tasigna (nilotinib), which is indicated for the first-line treatment of paediatric patients

Latest news

More from news
Approximately 5 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    The successes of Gilenya, Afinitor/Votubia, Galvus, Tasigna and Jakavi - as well as its generics arm, Sandoz - mean that Novartis is now less than $500m behind Pfizer in second place.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer);

  • Interview: Harvey Berger and Timothy Clackson, Ariad Interview: Harvey Berger and Timothy Clackson, Ariad

    recommended for use in patients who have grown resistance to Tasigna (nilotinib) and Gleevec/Glivec (imatinib mesylate) from Novartis and Bristol-Myers Squibb's Sprycel (dasatinib). ... and Tasigna.

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    There are also global direct-to-patient access programmes for Gleevec and Tasigna, life-saving therapies for chronic myeloid leukemia and gastrointestinal stromal tumours. ... Through the programmes, Gleevec and Tasigna were supplied to more than 42, 000

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....